Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS-论文-万方医学网

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS

导出原文传递

翻译打印收藏纠错

作者： Kuhle, Jens ^[1] ; Daizadeh, Nadia ^[2] ; Benkert, Pascal ^[3] ; Maceski, Aleksandra ; Barro, Christian ; Michalak, Zuzanna ; Sormani, Maria Pia ; Godin, Jean ; Shankara, Srinivas ; Samad, Tarek A. ; Jacobs, Alan ; Chung, Luke ; Rosch, Nora ; Kaiser, Carina ; Mitchell, Colin P. ; Leppert, David ; Havari, Evis ; Kappos, Ludwig

作者单位： Sanofi ^[1] Univ Hosp Basel,Univ Basel ^[2] Dept Hlth Sci,Univ Genoa ^[3]

关键词 Alemtuzumab biomarkers clinical trials randomized controlled highly active disease NfL neurofilament light chain multiple sclerosis MULTIPLE-SCLEROSIS BIOMARKER

发布时间 2022-07-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS

相似文献

相关期刊

检索历史清除